Outlook Therapeutics (NASDAQ:OTLK - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $30.00 target price on the stock.
Several other equities analysts also recently issued reports on OTLK. Chardan Capital reissued a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. BTIG Research decreased their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, November 29th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $28.07.
Read Our Latest Stock Report on OTLK
Outlook Therapeutics Price Performance
OTLK traded down $0.09 during midday trading on Friday, reaching $2.10. 672,014 shares of the company's stock were exchanged, compared to its average volume of 1,104,785. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85. The stock has a market capitalization of $52.40 million, a PE ratio of -0.23 and a beta of 0.53. The business's 50-day moving average price is $2.78 and its 200 day moving average price is $5.39.
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.06. As a group, analysts expect that Outlook Therapeutics will post -2.33 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in Outlook Therapeutics during the second quarter worth about $75,000. Christensen King & Associates Investment Services Inc. purchased a new stake in shares of Outlook Therapeutics during the 3rd quarter worth about $55,000. Barclays PLC increased its position in Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company's stock worth $111,000 after purchasing an additional 18,249 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Outlook Therapeutics in the second quarter valued at approximately $232,000. Finally, XTX Topco Ltd purchased a new position in Outlook Therapeutics in the third quarter valued at approximately $199,000. 11.20% of the stock is owned by hedge funds and other institutional investors.
Outlook Therapeutics Company Profile
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Recommended Stories
![Analyst Recommendations for Outlook Therapeutics (NASDAQ:OTLK)](https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=OTLK)
Before you consider Outlook Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.
While Outlook Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.